The role of essential phospholipids in the complex therapy of non-alcoholic fatty liver disease: a case-control study

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The article demonstrates the potentiation of the clinical effect of essential phospholipids (EPLы) in relation to liver fibrosis in non-alcoholic fatty liver disease (NAFLD), when using complex therapy for NAFLD that meets current specialized clinical guidelines, with the inclusion of EPL in the treatment regimen.

Objective. Comparative assessment of liver stiffness after EPL therapy and without the use of EPL in the context of compliance with specialized clinical guidelines.

Methods. All patients received adequate therapy for NAFLD. In 58 patients, the drug from the EPL group was included in the treatment regimen (experimental group), in 52 patients, the drug was not included (control group).

Results. The presence of a statistically significant difference was determined between patients who received treatment with and without the use of EPL in the regimen.

Conclusion. It is recommended to include EPL in the complex therapy of NAFLD.

Full Text

Restricted Access

About the authors

Larisa V. Tarasova

I.N. Ulyanov Chuvash State University

Author for correspondence.
Email: tlarisagast18@mail.ru
ORCID iD: 0000-0003-1496-0689
Scopus Author ID: 35777248600

Dr. Sci. (Med.), Head of the Department of Hospital Therapy

Russian Federation, Cheboksary

Yulia V. Tsyganova

I.N. Ulyanov Chuvash State University

Email: tlarisagast18@mail.ru
ORCID iD: 0000-0002-8339-9496

Candidate of Medical Sciences, Associate Professor of the Department of Hospital Therapy

Russian Federation, Cheboksary

Igor Yu. Filippov

I.N. Ulyanov Chuvash State University

Email: tlarisagast18@mail.ru
ORCID iD: 0000-0001-7653-1068

senior lecturer of the Department of Hospital Therapy

Russian Federation, Cheboksary

References

  1. Демидова Т.Ю., Ушанова Ф.О. Неалкогольная жировая болезнь печени: аспекты ведения коморбидного пациента. Терапевтический архив. 2023;95(10):888–895. doi: 10.26442/00403660.2023.10.202435. [Demidova T.Y., Ushanova F.O. Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review. Ter Arkh. 2023;95(10):888–95. doi: 10.26442/00403660.2023.10.202435. (In Russ.)].
  2. Osipova D., Kokoreva K., Lazebnik L., et al. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved. Front Pharmacol. 2022;13:797923. doi: 10.3389/fphar.2022.797923.
  3. Wupperfeld D., Fricker G., Bois De Fer B., et al. Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines. Lipids Health Dis. 2022;24;21(1):91. doi: 10.1186/s12944-022-01698-8.
  4. Ivashkin V.T., Maevskaya M.V., Shirokova E.N., et al. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes. 2021;8(3):369–82. doi: 10.1007/s40801-021-00250-x.
  5. Dajani A.I., Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J. Clin. Cases. 2020;8(21):5235–49. doi: 10.12998/wjcc.v8.i21.5235.
  6. Stefan N., Hartleb M., Popovic B., et al. Essential phospholipids efficacy in improving hepatic steatosis in patients with MASLD associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity – a randomized and controlled, double-blind, phase IV study. The Liver Meeting: Late Breaking abstract Supplement. Nov. 15–19, 2023. San Diego, CA.
  7. Valentino G., Zivko C., Weber F., et al. Synergy of Phospholipid-Drug Formulations Significantly Deactivates Profibrogenic Human Hepatic Stellate Cells. Pharmaceutics. 2019;11(12):676. doi: 10.3390/pharmaceutics11120676.
  8. Pan Y., et al. Effectiveness of polyene phosphatidylcholine in metabolic-associated fatty liver disease treatment: a real-world study in China. EASL Congress, 2024. Milan, Italy. 5–8 June, 2024. Poster.
  9. Manuc T., Preda C.M., Istratescu D., et al. Sylimarin Versus Essential Phospholipids in Metabolic Associated Steatotic Liver Disease (MASLD) - A Prospective Comparative Randomized Trial. Maedica (Bucur). 2024;19(1):9–16. doi: 10.26574/maedica.2024.19.1.9.
  10. Stefan N., Hartleb M., Popovic B., et al. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial. Trials. 2024;25:374. doi: 10.1186/s13063-024-08208-4.
  11. Лазебник Л.Б., Голованова Е.В., Туркина С.В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(185):4–52. doi: 10.31146/1682-8658-ecg-185-1-4-52. [Lazebnik L.B., Golovanova E.V., Turkina S.V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroentero logy. 2021;185(1):4–52. (In Russ.)]. doi: 10.31146/1682-8658-ecg-185-1-4-52.
  12. Диомидова В.Н., Тарасова Л.В., Цыганова Ю.В. и др. Ультразвуковая эластография печени с технологией затухающего сигнала позволяет оценить степень стеатоза и осуществлять динамическое наблюдение эффективности лечения НАЖБП. Экспериментальная и клиническая гастроэнтерология. 2020;9(181):45–54. doi: 10.31146/1682-8658-ecg-181-9-45-54. [Diomidova V.N., Tarasova L.V., Tsyganova Yu.V., et al. Ultrasound hepatic elastography with decaying signal technology allows assessing the degree of steatosis and dynamic monitoring of the eff ectiveness of NAFLD treatment. Experimental and Clinical Gastroenterology. 2020;181(9):45–54. (In Russ.)]. doi: 10.31146/1682-8658-ecg-181-9-45-54.
  13. Тарасова Л.В., Цыганова Ю.В., Опалинс-кая И.В., Иванова А.Л. Обзор методов лабораторной диагностики, применяемых при неалкогольной жировой болезни печени (НАЖБП) и алкогольной болезни печени (АБП) на современном этапе. Экспериментальная и клиническая гастроэнтерология. 2019;4(164):72–7. doi: 10.31146/1682-8658-ecg-164-4-72-77. [Tarasova L.V., Tsyganova Yu.V., Opalinskaya I.V., Ivanova A.L. Overview of laboratory diagnostic methods used in nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) at the modern stage. Experimental and Clinical Gastroenterology. 2019;164(4): 72–77. (In Russ.)]. doi: 10.31146/1682-8658-ecg-164-4-72-77.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Analysis of liver stiffness values ​​after treatment depending on the fact of taking EFL

Download (53KB)
Indexing metadata

Copyright (c) 2025 Bionika Media